Does anyone know if the LANI royalties will be 50/50 in Japan, or will DS get all the Japanese profits and Biota get other markets? I'm happy to be corrected, but it is slightly more complicated than that and no-one has seen the actual contract. Royalties are split, but DS is commercialising LANI by themselves. I was concerned Biota would get nothing from Japan, but the March 30 announcement clarified it. "Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market." So DS will take the lions share. Imagine DS as GSK, plus they get half of royalty. 'Half' is not meant to imply 50%, I'm just trying to show you that Biota get some money, but DS get more, in Japan.
What PA and other posters are rightly excited about is rest of world rights. If you read the May 1st presentation from Biota or anything they have said for a while it is pretty clear they will be trying to sell those rights. IIRC they have been trying to sell them since 2004 (hazy memory, too lazy to look up notes). So Biota may end up with a deal like they have with GSK on Relenza, except they share the royalties with DS (hazy again, where are those notes)
Others please correct any errors in my poor memory.
BTA Price at posting:
$1.14 Sentiment: None Disclosure: Held
